{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:32:15Z","timestamp":1789965135977,"version":"4.0.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Womens Ment Health"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00737-023-01378-1","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T11:02:23Z","timestamp":1697194943000},"page":"35-44","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1007","volume":"27","author":[{"given":"Meilian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhuo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaping","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1942-3073","authenticated-orcid":false,"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"1378_CR1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA","DOI":"10.1176\/appi.books.9780890425596"},{"key":"1378_CR2","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S2215-0366(19)30292-5","volume":"6","author":"IA Cristea","year":"2019","unstructured":"Cristea IA, Naudet F (2019) US Food and Drug Administration approval of esketamine and brexanolone. The Lancet Psychiatry 6:975\u2013977","journal-title":"The Lancet Psychiatry"},{"key":"1378_CR3","doi-asserted-by":"publisher","first-page":"699740","DOI":"10.3389\/fpsyt.2021.699740","volume":"12","author":"AN Edinoff","year":"2021","unstructured":"Edinoff AN, Odisho AS, Lewis K, Kaskas A, Hunt G, Cornett EM, Kaye AD, Kaye A, Morgan J, Barrilleaux PS, Lewis D, Viswanath O, Urits I (2021) Brexanolone, a GABA(A) Modulator, in the treatment of postpartum depression in adults: a comprehensive review. Front Psych 12:699740","journal-title":"Front Psych"},{"key":"1378_CR4","first-page":"627","volume":"26","author":"A Eldar-Lissai","year":"2020","unstructured":"Eldar-Lissai A, Cohen JT, Meltzer-Brody S, Gerbasi ME, Chertavian E, Hodgkins P, Bond JC, Johnson SJ (2020) Cost-effectiveness of brexanolone versus selective serotonin reuptake inhibitors for the treatment of postpartum depression in the United States. J Manag Care Spec Pharm 26:627\u2013638","journal-title":"J Manag Care Spec Pharm"},{"key":"1378_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jad.2022.09.143","volume":"320","author":"CN Epperson","year":"2023","unstructured":"Epperson CN, Rubinow DR, Meltzer-Brody S, Deligiannidis KM, Riesenberg R, Krystal AD, Bankole K, Huang MY, Li H, Brown C, Kanes SJ, Lasser R (2023) Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program. J Affect Disord 320:353\u2013359","journal-title":"J Affect Disord"},{"key":"1378_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40263-019-00605-7","volume":"33","author":"A Frieder","year":"2019","unstructured":"Frieder A, Fersh M, Hainline R, Deligiannidis KM (2019) Pharmacotherapy of postpartum depression: current approaches and novel drug development. CNS Drugs 33:265\u2013282","journal-title":"CNS Drugs"},{"key":"1378_CR7","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/pds.4672","volume":"27","author":"C Fukazawa","year":"2018","unstructured":"Fukazawa C, Hinomura Y, Kaneko M, Narukawa M (2018) Significance of data mining in routine signal detection: analysis based on the safety signals identified by the FDA. Pharmacoepidemiol Drug Saf 27:1402\u20131408","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1378_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000510703","volume":"90","author":"C Gastaldon","year":"2021","unstructured":"Gastaldon C, Raschi E, Kane JM, Barbui C, Schoretsanitis G (2021) Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system. Psychother Psychosom 90:41\u201348","journal-title":"Psychother Psychosom"},{"key":"1378_CR9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fpsyt.2017.00248","volume":"8","author":"J Hahn-Holbrook","year":"2017","unstructured":"Hahn-Holbrook J, Cornwell-Hinrichs T, Anaya I (2017) Economic and health predictors of national postpartum depression prevalence: a systematic review, meta-analysis, and meta-regression of 291 studies from 56 countries. Front Psych 8:248","journal-title":"Front Psych"},{"key":"1378_CR10","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00213-013-3316-1","volume":"231","author":"L Hantsoo","year":"2014","unstructured":"Hantsoo L, Ward-O\u2019Brien D, Czarkowski KA, Gueorguieva R, Price LH, Epperson CN (2014) A randomized, placebo-controlled, double-blind trial of sertraline for postpartum depression. Psychopharmacology 231:939\u2013948","journal-title":"Psychopharmacology"},{"key":"1378_CR11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S0140-6736(17)31264-3","volume":"390","author":"S Kanes","year":"2017","unstructured":"Kanes S, Colquhoun H, Gunduz-Bruce H, Raines S, Arnold R, Schacterle A, Doherty J, Epperson CN, Deligiannidis KM, Riesenberg R, Hoffmann E, Rubinow D, Jonas J, Paul S, Meltzer-Brody S (2017a) Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet (london, England) 390:480\u2013489","journal-title":"Lancet (london, England)"},{"key":"1378_CR12","doi-asserted-by":"crossref","unstructured":"Kanes SJ, Colquhoun H, Doherty J, Raines S, Hoffmann E, Rubinow DR, Meltzer-Brody S (2017b) Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression. Human psychopharmacology 32:e2576","DOI":"10.1002\/hup.2576"},{"key":"1378_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ogc.2020.05.001","volume":"47","author":"EB Kroska","year":"2020","unstructured":"Kroska EB, Stowe ZN (2020) Postpartum depression: identification and treatment in the clinic setting. Obstet Gynecol Clin North Am 47:409\u2013419","journal-title":"Obstet Gynecol Clin North Am"},{"key":"1378_CR14","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/S0140-6736(18)31551-4","volume":"392","author":"S Meltzer-Brody","year":"2018","unstructured":"Meltzer-Brody S, Colquhoun H, Riesenberg R, Epperson CN, Deligiannidis KM, Rubinow DR, Li H, Sankoh AJ, Clemson C, Schacterle A, Jonas J, Kanes S (2018) Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet (london, England) 392:1058\u20131070","journal-title":"Lancet (london, England)"},{"key":"1378_CR15","doi-asserted-by":"crossref","unstructured":"Noguchi Y, Tachi T, Teramachi H (2021) Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Briefings in bioinformatics 22:bbab347","DOI":"10.1093\/bib\/bbab347"},{"key":"1378_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A (2013) Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res 22:57\u201369","journal-title":"Stat Methods Med Res"},{"key":"1378_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1146\/annurev-clinpsy-050212-185612","volume":"9","author":"MW O'Hara","year":"2013","unstructured":"O\u2019Hara MW, McCabe JE (2013) Postpartum depression: current status and future directions. Annu Rev Clin Psychol 9:379\u2013407","journal-title":"Annu Rev Clin Psychol"},{"key":"1378_CR18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1177\/0897190020979627","volume":"35","author":"E Patatanian","year":"2022","unstructured":"Patatanian E, Nguyen DR (2022) Brexanolone: a novel drug for the treatment of postpartum depression. J Pharm Pract 35:431\u2013436","journal-title":"J Pharm Pract"},{"key":"1378_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1060028019873320","volume":"54","author":"JG Powell","year":"2020","unstructured":"Powell JG, Garland S, Preston K, Piszczatoski C (2020) Brexanolone (Zulresso): finally, an FDA-approved treatment for postpartum depression. Ann Pharmacother 54:157\u2013163","journal-title":"Ann Pharmacother"},{"key":"1378_CR20","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.cpr.2013.10.004","volume":"33","author":"LE Sockol","year":"2013","unstructured":"Sockol LE, Epperson CN, Barber JP (2013) Preventing postpartum depression: a meta-analytic review. Clin Psychol Rev 33:1205\u20131217","journal-title":"Clin Psychol Rev"},{"key":"1378_CR21","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1056\/NEJMcp1607649","volume":"375","author":"DE Stewart","year":"2016","unstructured":"Stewart DE, Vigod S (2016) Postpartum depression. N Engl J Med 375:2177\u20132186","journal-title":"N Engl J Med"},{"key":"1378_CR22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1146\/annurev-med-041217-011106","volume":"70","author":"DE Stewart","year":"2019","unstructured":"Stewart DE, Vigod SN (2019) Postpartum depression: pathophysiology, treatment, and emerging therapeutics. Annu Rev Med 70:183\u2013196","journal-title":"Annu Rev Med"},{"key":"1378_CR23","doi-asserted-by":"publisher","first-page":"950004","DOI":"10.3389\/fphar.2022.950004","volume":"13","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Dai X, Li W (2022) Comparative efficacy and acceptability of pharmacotherapies for postpartum depression: a systematic review and network meta-analysis. Front Pharmacol 13:950004","journal-title":"Front Pharmacol"}],"container-title":["Archives of Women's Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00737-023-01378-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00737-023-01378-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00737-023-01378-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T18:11:51Z","timestamp":1705428711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00737-023-01378-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1378"],"URL":"https:\/\/doi.org\/10.1007\/s00737-023-01378-1","relation":{},"ISSN":["1434-1816","1435-1102"],"issn-type":[{"value":"1434-1816","type":"print"},{"value":"1435-1102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"25 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}